Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase II Multi-Institutional Study of Concurrent Radiotherapy, Palbociclib, and Hormone Therapy for Treatment of Bone Metastasis in Breast Cancer Patients

Trial Profile

A Phase II Multi-Institutional Study of Concurrent Radiotherapy, Palbociclib, and Hormone Therapy for Treatment of Bone Metastasis in Breast Cancer Patients

Not yet recruiting
Phase of Trial: Phase II

Latest Information Update: 08 Oct 2018

At a glance

  • Drugs Palbociclib (Primary) ; Anastrozole; Exemestane; Fulvestrant; Letrozole; Tamoxifen
  • Indications Advanced breast cancer; Bone metastases
  • Focus Therapeutic Use
  • Acronyms ASPIRE
  • Most Recent Events

    • 08 Oct 2018 New trial record
    • 04 Oct 2018 According to a Pfizer media release, Pfizer Investigator Research Exchange (ASPIRE) Breast Cancer Research Awards of more than 3$ million has been granted to four studies including this.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top